title: [The feature of cardial remodeling process at Doxorubicin chemotherapy and idiopathic dilatative cardiomyopathy].
abstract: The aim of the study was the evaluation of structural-functional data of the left ventricle (LV) at doxorubicin chemotherapy and idiopathic dilatative cardiomyopathy. Monitoring of 99 patients had been performed: 49 with onco-hematological diseases and 50 with idiopathic dilatative cardiomyopathy. According to the total dose of doxorubicin the patients had been divided to three sub-groups: I subgroup -- 232.2+/-5.8 mg/m(2), II subgroup - 388+/-15.3mg/m(2), III subgroup - 533.1+/-13.6 mg/m(2). It had been revealed the dose-depending evolution of cardiotoxic effect of doxorubicin leading to the development of anthracyclic cardiomyopathy. At anthracyclic cardiomyopathy LV undergoes the same structural-functional changes as the idiopathic dilatative cardiomyopathy. The cardiotoxic effect of doxorubicin is revealed already at law summary dose of 232 mg/m(2), at "critical dose" 356-388 mg/m(2) develops diastolic dysfunction of LV with clinical manifestation of heart failure, and by summary dose of 533 mg/m(2) develops anthracyclic dilatative cardiomyopathy with systolic-diastolic dysfunction of LV and with clinical manifestation of the heart failure.
authors.forename: N A
authors.initials: NA
authors.lastname: Katamadze
authors.forename: K P
authors.initials: KP
authors.lastname: Lartsuliani
authors.forename: N N
authors.initials: NN
authors.lastname: Begishvili
authors.forename: Kh V
authors.initials: KhV
authors.lastname: Dundua
authors.forename: M P
authors.initials: MP
authors.lastname: Kiknadze
mesh_terms: D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D002311:Cardiomyopathy, Dilated / Q000139:chemically induced / Q000503:physiopathology*; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D019337:Hematologic Neoplasms / Q000188:drug therapy*; D006801:Humans; D008297:Male; D009200:Myocardial Contraction / Q000187:drug effects; D012307:Risk Factors; D020257:Ventricular Remodeling / Q000187:drug effects / Q000502:physiology
chemical_list: D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin